耀才团队: 恒指10天线沽压显着
耀才证券研究部团队称,美股隔晚(15日)先高後回稳,因应生化科技公司Moderna研发的新冠肺炎疫苗,在临床试验者身上产生免疫反应,另外工业生产录得1959年以来最大单月增幅胜预期,令市场有所憧憬,道指最段抽高逾400点,惟部分科网巨头仍然受压,大市尾段回落。中美关系之进展仍然为市场的隐忧,但有指特朗普突然叫停制裁中国及香港的主要官员,令紧张的状态暂缓。目前恒指未能重返10天线之上,今日(16日)中国将公布第二季GDP,关於第二季经济复苏的势头,留意资金流的表现。中芯(00981.HK)A股今日正式挂牌,竞价市段大升逾2倍以上,留意AH股差价能否得以收窄。
从技术上看,恒指昨日低见25,254点後跌由收窄,至今未有正式跌破6月10日高位25,303点,暂不建议投资者短期後市看淡,只要未失守此关,在整固过後指数仍有条件重上250天线并再创月内新高。
(笔者为证监会持牌人)~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.